KBC Group’s Global Blood Therapeutics, Inc. GBT Stock Holding History

KBC Group’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-425	Closed	-$11K	–	1351
2021 Q3	$11K	Sell	425 -425	-50%	-$12.5K	﹤0.01%	1286
2021 Q2	$30K	Hold	850	–	–	﹤0.01%	1266
2021 Q1	$34K	Hold	850	–	–	﹤0.01%	1277
2020 Q4	$202K	Hold	850	–	–	﹤0.01%	1251
2020 Q3	$46K	Hold	850	–	–	﹤0.01%	1209
2020 Q2	$54K	Buy	850 +425	+100%	+$29.2K	﹤0.01%	1247
2020 Q1	$22K	Hold	425	–	–	﹤0.01%	1250
2019 Q4	$34K	Sell	425 -405	-49%	-$24K	﹤0.01%	1437
2019 Q3	$40K	Buy	830 +405	+95%	+$21.1K	﹤0.01%	1395
2019 Q2	$22K	Hold	425	–	–	﹤0.01%	1406
2019 Q1	$22K	Hold	425	–	–	﹤0.01%	1370
2018 Q4	$17K	Hold	425	–	–	﹤0.01%	1280
2018 Q3	$16K	Hold	425	–	–	﹤0.01%	1373
2018 Q2	$19K	Hold	425	–	–	﹤0.01%	1269
2018 Q1	$21K	Hold	425	–	–	﹤0.01%	1250
2017 Q4	$17K	Buy	+425	New	+$15.9K	﹤0.01%	1241

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

KBC Group's GBT Position: Q4 2021 in Review

KBC Group sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2021, closing a stake of 425 shares — an estimated $11K sold.

KBC Group first reported a position in GBT in Q4 2017 and held it in 16 quarters. The position peaked at $202K in Q4 2020. 206 funds tracked by Wall St. Rank hold GBT as of Q4 2021.

KBC Group reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
KBC Group sold 425 Global Blood Therapeutics, Inc. shares in Q4 2021, an estimated $11K.
KBC Group first reported a position in Global Blood Therapeutics, Inc. in Q4 2017 and held it in 16 quarters.
KBC Group's Global Blood Therapeutics, Inc. position peaked at $202K in Q4 2020.
206 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2021.

Based on KBC Group's 13F filing for Q4 2021, filed 3 Feb 2022.